Civica Takes First Foray Into Biosimilars With GeneSys Insulins Partnership
Initiative Will Produce Biosimilars Of Lantus, Humalog And Novolog
Non-profit generics firm Civica is partnering with GeneSys Biologics to make affordable biosimilars of Lantus, Humalog and Novolog for the US market, which it aims to sell at $30 a vial or $55 per pack of cartridges.
You may also be interested in...
As it continues plans to roll out low-cost insulin biosimilar products, CivicaScript has augmented its existing product offering via a collaboration with specialty pharmacy SortPak.
Biosimilar insulin producers are facing calls to improve patient affordability after Eli Lilly implemented a $35 price cap on copays for its insulins in the private market and for the uninsured.
Ypsomed AG will manufacture insulin dosing injector pens for non-profit Civica. Civica has also paired up with AmerisourceBergen for generics supply chain support across the US.